ViCentra, the Utrecht-based medtech company behind the Kaleido insulin patch pump, has raised $85M (~€72M) in Series D funding to scale manufacturing, expand across Europe, and prepare for entry into the US.
The round was led by Innovation Industries, with participation from existing investors Partners in Equity, Invest-NL, EQT Life Sciences, and Health Innovations.
“ViCentra is redefining insulin pump therapy with a platform that combines clinical performance with design simplicity and wearability,” said Caaj Greebe, Partner at Innovation Industries.
A design-first approach to diabetes care
The firm’s insulin pump differs from traditional insulin pumps by focusing on flexibility, personalisation, and integration with automated insulin delivery systems. The device pairs with Diabeloop’s DBLG1 and DBLG2 algorithms and is compatible with the Dexcom continuous glucose monitor (CGM).
Users can also customise the pump with ten different aluminium shells, blending functionality with style. Kaleido is already available in Germany, France, and the Netherlands, where demand has exceeded expectations.
Advertisement
Next phase of growth
The fresh capital will support:
- Scaling production capacity to meet surging European demand
- The launch of Kaleido 2 across Europe
- Preparations for US market entry
“Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed,” said Tom Arnold, CEO of ViCentra. “This funding allows us to accelerate expansion and better serve the diabetes community globally.”
The company will showcase its developments at the upcoming European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna later this month.
